Andy Hurwitz, Ph.D. Head of Preclinical Research
Dr. Hurwitz leads preclinical research for AgenTus where he is responsible for the preclinical evaluation of TCR candidates identified in the Cell Therapy Program as well as translational development of heat shock protein-based vaccines.
Dr. Hurwitz is an expert in T cell responses to antigens relevant to cancer and autoimmune disease.
Prior to Agenus, Dr. Hurwitz was a Principal Investigator in the Cancer and Inflammation Program at the National Cancer Institute (NIH).
His laboratory developed several TCR-based experimental models used to study T cell tolerance to tumor antigens.
Dr. Hurwitz received his Ph.D. from the Albert Einstein College of Medicine and did his postdoctoral training at University of California, Berkeley.
Prior to the NIH, he was on the faculty at SUNY Upstate Medical University.